Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Share-based Compensation: 2015-2024

Historic Share-based Compensation for Corvus Pharmaceuticals (CRVS) over the last 10 years, with Dec 2024 value amounting to $3.0 million.

  • Corvus Pharmaceuticals' Share-based Compensation rose 70.16% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.6 million, marking a year-over-year increase of 65.27%. This contributed to the annual value of $3.0 million for FY2024, which is 39.87% up from last year.
  • Latest data reveals that Corvus Pharmaceuticals reported Share-based Compensation of $3.0 million as of FY2024, which was up 39.87% from $2.1 million recorded in FY2023.
  • Over the past 5 years, Corvus Pharmaceuticals' Share-based Compensation peaked at $5.7 million during FY2020, and registered a low of $2.1 million during FY2023.
  • Its 3-year average for Share-based Compensation is $2.6 million, with a median of $2.7 million in 2022.
  • Its Share-based Compensation has fluctuated over the past 5 years, first plummeted by 36.39% in 2022, then surged by 39.87% in 2024.
  • Yearly analysis of 5 years shows Corvus Pharmaceuticals' Share-based Compensation stood at $5.7 million in 2020, then dropped by 26.36% to $4.2 million in 2021, then plummeted by 36.39% to $2.7 million in 2022, then declined by 20.25% to $2.1 million in 2023, then spiked by 39.87% to $3.0 million in 2024.